IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10322111 B1

PDFFull Text
Date of Patent:
Jun. 18, 2019

Filed:

Feb. 08, 2016

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Applicant:

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Gary J. Bridger, Bellingham, WA (US);

Renato T. Skerlj, Newton, MA (US);

Al Kaller, Vancouver, CA;

Curtis Harwig, Vancouver, CA;

David Earl Bogucki, Surrey, CA;

Trevor R. Wilson, Langley, CA;

Jason B. Crawford, Burnaby, CA;

Ernest J. McEachern, White Rock, CA;

Bem Atsma, Langley, CA;

Siqiao Nan, ShenZhen, CN;

Yuanxi Zhou, Richmond, CA;

Dominique Schols, Herent, BE;

Christopher Dennis Smith, Toronto, CA;

Maria Rosario DiFluri, Burnaby, CA;

Assignee:

GENZYME CORPORATION, Cambridge, MA (US);

Attorney:

Lando & Anastasi, LLP

Primary Examiner:

Zinna Northington Davis

Int. Cl.
CPC ...
C07D 401/12 (2006.01); A61K 31/47 (2006.01); A61K 31/4184 (2006.01); A61K 31/415 (2006.01); A61K 31/495 (2006.01); A61K 31/50 (2006.01); C07D 235/14 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 471/04 (2006.01); C07D 471/06 (2006.01); C07D 491/04 (2006.01); C07D 491/052 (2006.01); A61K 31/436 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/497 (2006.01); A61K 31/4985 (2006.01); A61K 31/502 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4184 (2013.01); A61K 31/415 (2013.01); A61K 31/436 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/495 (2013.01); A61K 31/497 (2013.01); A61K 31/4985 (2013.01); A61K 31/50 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); C07D 235/14 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 471/04 (2013.01); C07D 471/06 (2013.01); C07D 491/04 (2013.01); C07D 491/052 (2013.01); Y02A 50/411 (2018.01);
Abstract

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Find Patent Forward Citations

Loading…